Coenzyme Q10 in neuromuscular and neurodegenerative disorders

Current Drug Targets

Volumn 11, Issue 1, 2010, Pages 111-121

  Mancuso, M ^a   Orsucci, D ^a   Volpi, L ^a   Calsolaro, V ^a   Siciliano, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Coenzyme Q10; CoQ10 deficiency; Idebenone; Mitochondria; Mitochondrial diseases; Neurodegeneration; Statins

Indexed keywords

ADENOSINE TRIPHOSPHATE; ATORVASTATIN; CREATINE; CREATINE KINASE; EZETIMIBE; IDEBENONE; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; REMACEMIDE; SIMVASTATIN; THIOCTIC ACID; UBIDECARENONE; DRUG DERIVATIVE; UBIQUINONE;

ADULT; ANTIOXIDANT ACTIVITY; CASE REPORT; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; HYPERCHOLESTEROLEMIA; MALE; MITOCHONDRIAL RESPIRATION; MYOPATHY; NEUROMUSCULAR DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; ANIMAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; METABOLISM; PHYSIOLOGY;

ANIMALS; HUMANS; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; NEUROMUSCULAR DISEASES; UBIQUINONE;

EID: 77949440226     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790031018     Document Type: Review

References (80)

1. Dallner G, Sindelar PJ. Regulation of ubiquinone metabolism. Free Radic Biol Med 2000; 29: 285-94.
2. Mizuno K, Tanaka M, Nozaki S, Mizuma H, Ataka S, Tahara T, et al. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition 2008; 24: 293-9.
3. DiMauro S, Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep 2007; 27: 125-37.
4. Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64: 713-5.
5. Hershey AD, Powers SW, Vockell AL, Lecates SL, Ellinor PL, Segers A, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007; 47: 73-80.
6. Khan M, Gross J, Haupt H, Jainz A, Niklowitz P, Scherer H, et al. A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium. Otolaryngol Head Neck Surg 2007; 136: 72-7.
7. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007; 21: 297-306.
8. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Phys 2005; 72: 1065-70.
9. Belardinelli R, Muçaj A, Lacalaprice F, Solenghi M, Seddaiu G, Principi F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006; 27: 2675-81.
10. Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, et al Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 2008; 52: 1435-41.
11. Land JM, Heales SJ, Duncan AJ, Hargreaves IP. Some observations upon biochemical causes of ataxia and a new disease entity ubiquinone, CoQ10 deficiency. Neurochem Res 2007; 32: 837-43.
12. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348: 2656-68.
13. Noji H, Yoshida M. The rotary machine of the cell, ATP synthase. J Biol Chem 2001; 276: 1665-68.
14. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis 2006; 10: 59-73.
15. Fato R, Bergamini C, Leoni S, Lenaz G. Mitochondrial production of reactive oxygen species: role of complex I and quinone analogues. Biofactors 2008; 32: 31-9.
16. Genova ML, Pich MM, Bernacchia A, Bianchi C, Bovina A, Bovina C, et al. The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann N Y Acad Sci 2004; 1011: 86-100.
17. Grivennikova VG, Vinogradov AD. Generation of superoxide by the mitochondrial Complex I. Biochim Biophys Acta 2006; 1757: 553-61.
18. Di Lisa F, Kaludercic N, Carpi A, Menabò R, Giorgio M. Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamine oxidase. Basic Res Cardiol 2009; 104: 131-9.
19. Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol Dis 2005; 18: 618-27.
20. Ferrante RJ, Schulz JB, Kowall NW, Beal MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997; 753: 157-62.
21. Winkler-Stuck K, Wiedemann FR, Wallesch CW, Kunz WS. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J Neurol Sci 2004; 220: 41-8.
22. Kooncumchoo P, Sharma S, Porter J, Govitrapong P, Ebadi M. Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci 2006; 28: 125-41.
23. Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, et al. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 2008; 104: 1613-21.
24. Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis 2008; 14: 225-34.
25. Moreira PI, Santos MS, Sena C, Nunes E, Seiça R, Oliveira CR. CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp Neurol 2005; 196: 112-9.
26. Li G, Jack CR, Yang XF, Yang ES. Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: an in vivo volume MRI study. Biofactors 2008; 32: 169-78.
27. Ishrat T, Khan MB, Hoda MN, Yousuf S, Ahmad M, Ansari MA, et al. Coenzyme Q10 modulates cognitive impairment against intracerebroventri-cular injection of streptozotocin in rats. Behav Brain Res 2006; 171: 9-16.
28. McDonald SR, Sohal RS, Forster MJ. Concurrent administration of coenzyme Q10 and alpha-tocopherol improves learning in aged mice. Free Radic Biol Med 2005; 38: 729-36.
29. Kasparová S, Sumbalová Z, Bystrick?? P, Kucharská J, Liptaj T, Mlynárik V, et al. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem Int 2006; 48: 93-9.
30. Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, et al. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 2006; 1762: 616-26.
31. Orsucci D, Calsolaro V, Mancuso M, Siciliano G. Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease. CNS Neurol Disord Drug Targets 2009; 8: 222-31.
32. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, et al. Com-bination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006; 1762: 373-80.
33. Fetoni AR, Piacentini R, Fiorita A, Paludetti G, Troiani D. Water-soluble Coenzyme Q10 formulation (Q-ter) promotes outer hair cell survival in a guinea pig model of noise induced hearing loss (NIHL). Brain Res 2009; 1257: 108-16.
34. Fetoni AR, Ferraresi A, Greca CL, Rizzo D, Sergi B, Tringali G, et al. Antioxidant protection against acoustic trauma by coadministration of idebenone and vitamin E. Neuroreport 2008; 19: 277-81.
35. DiMauro S, Quinzii CM, Hirano M. Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest 2007; 117: 587-9.
36. Quinzii CM, López LC, Naini A, DiMauro S, Hirano M. Human CoQ10 deficiencies. Biofactors 2008; 32: 113-8.
37. Gempel K, Topaloglu H, Talim B, Schneiderat P, Schoser BG, Hans VH, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007; 130: 2037-44.
38. Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 2005; 62: 317-20.
39. Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest 2007; 117: 765-72.
40. Lòpez LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006; 79: 1125-9.
41. Quinzii CM, Naini A, Salviati L, Trevisson E, Navas P, Dimauro S, et al. A Mutation in Para-Hydroxybenzoate-Polyprenyl Transferase (COQ2) Causes Primary Coenzyme Q10 Deficiency. Am J Hum Genet 2006; 78: 345-9.
42. Quinzii CM, Kattah AG, Naini A, Akman HO, Mootha VK, DiMauro S, et al. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. Neurology 2005; 64: 539-41.
43. Le Ber I, Dubourg O, Benoist JF, Jardel C, Mochel F, Koenig M, et al. Muscle coenzyme Q10 deficiencies in ataxia with oculomotor apraxia 1. Neurology 2007; 68: 295-7.
44. Mollet J, Delahodde A, Serre V, Chretien D, Schlemmer D, Lombes A, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet 2008; 82: 623-30.
45. Lagier-Tourenne C, Tazir M, López LC, Quinzii CM, Assoum M, Drouot N, et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet 2008; 82: 661-72.
46. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, López LC, et al. A Nonsense Mutation in COQ9 Causes Autosomal-Recessive Neonatal-Onset Primary Coenzyme Q10 Deficiency: A Potentially Treatable Form of Mitochondrial Disease. Am J Hum Genet 2009; 84: 558-66.
47. Artuch R, Brea-Calvo G, Briones P, Aracil A, Galván M, Espinós C, et al. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci 2006; 246: 153-8.
48. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 2008; 358: 2849-50.
49. Rotig A, Mollet J, Rio M, Munnich A. Infantile and pediatric quinone deficiency diseases. Mitochondrion 2007; 7: S112-21.
50. Schaefer AM, McFarland R, Blakely EL, He L, Whittaker RG, Taylor RW, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008; 63: 35-9.
51. Montero R, Artuch R, Briones P, Nascimento A, García-Cazorla A, Vilaseca MA, et al. Muscle coenzyme Q10 concentrations in patients with probable and definite diagnosis of respiratory chain disorders. Biofactors 2005; 25: 109-15.
52. Miles MV, Miles L, Tang PH, Horn PS, Steele PE, DeGrauw AJ, et al. Systematic evaluation of muscle coenzyme Q10 content in children with mitochondrial respiratory chain enzyme deficiencies. Mitochondrion 2008; 8: 170-80.
53. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006; 1: CD004426.
54. Berbel-Garcia A, Barbera-Farre JR, Etessam JP, Salio AM, Cabello A, Gutierrez-Rivas E, et al. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004; 27: 187-91.
55. Haginoya K, Miyabayashi S, Kikuchi M, Kojima A, Yamamoto K, Omura K, et al. Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study. J Neurol Sci 2009; 278: 112-4.
56. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997; 37: 212-8.
57. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35: 235-42.
58. Montuschi P, Barnes PJ, Roberts LJ II. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004; 18: 1791-800.
59. Rodriguez MC, Tarnopolsky MA. Patients with dystrophinopathy show evidence of increased oxidative stress. Free Radic Biol Med 2003; 34: 1217-20.
60. Naccarati A, Molinu S, Mancuso M, Siciliano G, Migliore L. Cytogenetic damage in peripheral lymphocytes of mitochondrial disease patients. Neurol Sci 2000; 21: S963-5.
61. Tomasetti M, Littarru GP, Stocker R, Alleva R. Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic Biol Med 1999; 27: 1027-32.
62. Migliore L, Molinu S, Naccarati A, Mancuso M, Rocchi A, Siciliano G. Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. Mutagenesis 2004; 19: 43-9.
63. Marcoff L, Thompson PD. The Role of Coenzyme Q10 in Statin-Associated Myopathy - A Systematic Review. J Am Coll Cardiol 2007; 49: 2231-7.
64. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005; 62: 1709-12
65. Päivä H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78: 60-8.
66. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saftey 2006; 29: 703-12.
67. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, et al. Hokuriku lipid research group. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007; 195: e182-9.
68. Hargreaves IP, Lane A, Sleiman PM. The coenzyme Q10 status of the brain regions of Parkinson's disease patients. Neurosci Lett 2008; 447: 17-9.
69. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59: 1541-50.
70. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007; 64: 938-44.
71. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007; 68: 20-8.
72. Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23: 942-9.
73. Huntington Study Group; Neurology. A randomized, placebocontrolled trial of coenzyme Q10 and remacemide in Huntington's disease, 2001, 57, 397-404.
74. Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005; 65: 1834-6.
75. Sohmiya M, Tanaka M, Suzuki Y, Tanino Y, Okamoto K, Yamamoto Y. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 2005; 228: 49-53.
76. Kaufmann P, Thompson TL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trail of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009; 66: 235-44.
77. Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, et al. Antioxidant treatment of patients with Friedreich ataxia: fouryear follow-up. Arch Neurol 2005; 62: 621-6.
78. Tonon C, Lodi R. Idebenone in Friedreich's ataxia. Expert Opin Pharmacother 2008; 9: 2327-37.
79. Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008; 15: 1371-9.
80. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 878-86.